Published January 10, 2018
Regenerative medicine is a branch involved in the repair, replace and regenerate tissues and organs affected due to injury, disease or natural aging process. These medicines are having the ability to restore the functionality of cells and tissues and are used in various strategies like cell therapy, gene therapy, and tissue engineering.
Asia-Pacific Regenerative Medicines market share:
On the basis of application, the market is segmented into orthopedic, oncology, diabetes, cardiology and central nervous system. Among this oncology is having the largest share and fastest growth in the market.
Asia-Pacific Regenerative Medicines market size:
The market is valued at USD 17.625 Billion in 2017 and is expected to reach USD 51.453 Billion by 2024 at a CAGR of 23.8%.
The market is predominant in Asia-Pacific and it continues during the forecast period. North America is in its growing phase and is holding the largest in regenerative medicines market as the therapies are in the 3rd phase of clinical trials.
Asia-Pacific Regenerative Medicines market growth:
The major factors influencing the market growth are growing prevalence of chronic diseases such as bone and joint diseases and trauma emergencies, growing need for orthopedic surgeries, innovation in stem cell therapy, technological innovations and tissue engineering.
Asia-Pacific Regenerative Medicines industry analysis:
The market is majorly divided into products, application, therapy, material and agent type. On the basis of products it is segmented into cell-based and acellular and on the basis of therapy, the market is segmented into the cell, therapy, tissue and gene therapy. On the basis of application, the market is segmented into orthopedic, dermatology, cardiology, oncology and central nervous system. On the basis of material, the market is categorized into algae-derived alginate, synthetic polymer, polylactide- coglycolide, polyethylene glycol and hydrogels. Final segmentation is based on agent type it is into biologics, cell-based medical devices, and biopharmaceuticals.
Asia-Pacific Regenerative Medicines Market Outlook:
Regenerative medicines are those generally have the ability to repair, replace and regenerate tissues and organs of affected due to disease, injury and natural aging process. Many industries and firms are trying to develop new technologies and advancements in order to improve the market growth.
Asia-Pacific Regenerative Medicines Market Trends:
Recent acquisitions in biotechnology are leading the regenerative medical industry have favorable growth. Medtronic acquired heart wave international which is a provider of technologies for mechanical circulatory support for patient’s treatment. This acquisition further is projected to have the company by broadening its products portfolio.
Asia-Pacific Regenerative Medicines Market Research Report Includes:
Chapter 1 Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
Chapter 2 Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
Chapter 3 Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter’s Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.4 SWOT Analysis
3.5 Y-O-Y Analyses
Chapter 4 Market Dynamics
Chapter 5 Market Segmentation Analysis
Chapter 6 Market Segmentation by Product
6.2 Cell-based products
6.2.1 Allogeneic products
6.2.2 Autologous products
6.3 Acellular products
Chapter 7 Market Segmentation by Application
7.2 Orthopaedic and musculoskeletal disorders
7.5 Central nervous system diseases
7.8 Bone graft substitutes
Chapter 8 Market Segmentation by Therapy
8.2 Cell therapy
8.4 Tissue therapy
8.5 Gene therapy
Chapter 9 Market Segmentation by Material
9.2 Algae-derived alginate
9.3 Synthetic polymer
9.5 Poly-ethylene glycol
Chapter 10 Market Segmentation by Agent type
10.2.1 Autologous fibroblasts
10.2.2 Hematopoietic stem and progenitor cells
10.3 Cell-based medical devices
10.3.1 Allogenic fibroblasts
10.3.2 Cell extraction
10.4.1 Tricalcium phosphate
10.4.2 Osteogenic protein
Chapter 11 Market Segmentation by Geography
11.1.5 Australia & New Zealand
Chapter 12 Competitive Landscape
12.1 Mergers & Acquisitions, Joint Ventures, Collaborations, and Agreements
12.2 Market Share Analysis
12.3 Strategies Adopted By Top Companies
Chapter 13 Company Profiles
13.1 StemCells Inc.
13.1.1 Business Overview
13.1.2 Product portfolio
13.1.3 Key Strategy
13.1.4 Recent Developments
13.2 Mesoblast Ltd
13.3 Athersys Inc.
13.4 Neuralstem Inc.
13.5 Neo Stem Inc.
Chapter 14 Market Estimates and Forecast
14.1 Market Estimates and forecast 2018-2024(USD Billion)
14.1.1 Market Estimates and forecast by Product 2018-2024(USD Billion)
14.1.2 Market Estimates and forecast by Application 2018-2024(USD Billion)
14.1.3 Market Estimates and forecast by Therapy 2018-2024(USD Billion)
14.1.4 Market Estimates and forecast by Material 2018-2024(USD Billion)
14.1.5 Market Estimates and forecast by Agent type 2018-2024(USD Billion)
14.1.6 Market Estimates and forecast by geography 2018-2024(USD Billion)
Chapter 15 Market Insights
15.1 Insights of Industry Experts
15.2 Analyst Opinion (Market Understanding)
15.3 Investment Opportunities
Chapter 16 Appendix
16.1 List of Tables
16.2 List of Figures